HealthWarehouse.com Reports Results for First Quarter 2021
HealthWarehouse.com, Inc. (OTCQB: HEWA) reported a net loss of $131,025 for Q1 2021, an increase from a loss of $68,428 in Q1 2020. Despite this, the company achieved a positive Adjusted EBITDA of $124,114. Net sales declined by 16% to $3,818,285, driven by decreased consumer demand and lower website traffic. Prescription sales fell by 9.9%, and over-the-counter sales decreased by 36.8%. Operating expenses decreased by 5.2%. Gross profit was $2,651,875, reflecting a 7.8% decrease, but gross margin improved to 69.5% through strategic purchasing efforts.
- Adjusted EBITDA was $124,114, indicating operational efficiency.
- Gross margin improved to 69.5%, up from 63.5% year-over-year.
- Investment in technology aiming to enhance customer experience and operational efficiency.
- Net loss increased to $131,025 compared to $68,428 in Q1 2020.
- Net sales decreased by 16% from the previous year.
- Prescription sales dropped by 9.9%, and over-the-counter sales plummeted by 36.8%.
HealthWarehouse.com, Inc. (OTCQB: HEWA) announced today that it reported a net loss of
HealthWarehouse.com, a technology company with a focus on healthcare e-commerce, sells and delivers prescription medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (NABP). HealthWarehouse.com provides a platform focused on increasing access and reducing costs of healthcare products for consumers nationwide.
Joseph Peters, President and CEO, commented that the Company recently initiated a campaign directed at customers of subscription-model pharmacy schemes that charge premium prices for generic prescription medications in categories including erectile disfunction and hair loss.
“We are positioned well because we offer prescription medications at affordable prices without requiring customers to commit to recurring subscriptions, memberships or club fees, which are often hard to pause or cancel. We are targeting customers of Ro Pharmacy, Hims & Hers Health, Inc., and LifeMD, Inc. to offer them more affordable prices and the freedom to get their medications when they choose to.”
HealthWarehouse.com continues to invest in proprietary technology to remain at the forefront of new developments and offerings in the world of healthcare, noting a focus on patient experience, operational efficiency, and scalability.
“We continue to work every day on furthering our commitment to improving the pharmacy experience for our customers,” Peters said. “As we prepare for the integration and implementation of our new pharmacy and website platforms, we remain focused on improving the efficiency of our pharmacy workflow to seamlessly add new customers while maintaining high quality service to existing customers.
“At the same time, we are in the midst of developing and preparing to implement our new branding and marketing initiatives. The culmination of these efforts, along with our prior investment in robotics, will position HealthWarehouse.com as a technological leader in the industry, supporting both its direct-to-consumer (B2C) and healthcare partnership (B2B) business units. We are excited for the changes and advancements that 2021 is bringing as we continue to set the standard for affordable healthcare in America and provide transparency to our customers across the nation.”
2021 First Quarter Overview:
Net Sales: Net sales for the first quarter this year decreased to
Gross Profit: Gross profit for the first quarter of 2021 was
Operating Expenses: Operating expenses totaled
Net Loss and Adjusted EBITDA: The Company reported a net loss of
| HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
(Unaudited) |
||||||||
| For the Three Months Ended | ||||||||
| March 31, | ||||||||
2021 |
2020 |
|||||||
| Net sales | $ |
3,818,285 |
|
$ |
4,527,339 |
|
||
| Cost of sales |
|
1,166,410 |
|
|
1,650,513 |
|
||
| Gross profit |
|
2,651,875 |
|
|
2,876,826 |
|
||
| Operating expenses |
|
2,739,576 |
|
|
2,889,299 |
|
||
| Net income (loss) from operations |
|
(87,701 |
) |
|
(12,473 |
) |
||
| Interest expense |
|
(43,324 |
) |
|
(55,955 |
) |
||
| Net loss |
|
(131,025 |
) |
|
(68,428 |
) |
||
| Preferred stock: | ||||||||
| Series B convertible contractual dividends |
|
(85,558 |
) |
|
(85,558 |
) |
||
| Net loss attributable to common stockholders | $ |
(216,583 |
) |
$ |
(153,986 |
) |
||
| Per share data: | ||||||||
| Net loss - basic and diluted | $ |
(0.00 |
) |
$ |
(0.00 |
) |
||
| Series B convertible contractual dividends | $ |
(0.00 |
) |
$ |
(0.00 |
) |
||
| Net loss attributable to common stockholders - basic | ||||||||
| and diluted | $ |
(0.00 |
) |
$ |
(0.00 |
) |
||
| Weighted average common shares outstanding - Basic and diluted |
|
51,632,399 |
|
|
50,663,600 |
|
||
Use of Non-GAAP Financial Measures
HealthWarehouse.com, Inc. (the "Company") prepares its consolidated financial statements in accordance with the United States generally accepted accounting principles ("GAAP"). In addition to disclosing financial results prepared in accordance with GAAP, the Company discloses information regarding EBITDA and Adjusted EBITDA, which are commonly used. In addition to adjusting net income or net loss to exclude interest, taxes, depreciation and amortization (“EBITDA”), Adjusted EBITDA also excludes stock-based compensation, and certain nonrecurring charges. EBITDA and Adjusted EBITDA are not measures of performance defined in accordance with GAAP. However, Adjusted EBITDA is used internally in planning and evaluating the Company`s performance. Accordingly, management believes that disclosure of this metric offers lenders and other shareholders an additional view of the Company`s operations that, when coupled with GAAP results, provides a more complete understanding of the Company’s financial results.
Adjusted EBITDA should not be considered as an alternative to net income, net loss or to net cash provided by or used in operating activities as a measure of operating results or of liquidity. It may not be comparable to similarly titled measures used by other companies, and it excludes financial information that some may consider important in evaluating the Company`s performance.
Reconciliation of Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP) |
|||||||||||
| Three Months Ended | |||||||||||
| March 31, | |||||||||||
2021 |
2020 |
||||||||||
| Net loss | $ |
(131,025 |
) |
$ |
(68,428 |
) |
|||||
| Interest expense |
|
43,324 |
|
|
55,955 |
|
|||||
| Depreciation and amortization |
|
33,280 |
|
|
33,506 |
|
|||||
| EBITDA (non-GAAP) |
|
(54,421 |
) |
|
21,033 |
|
|||||
| Adjustments to EBITDA: | |||||||||||
| Stock-based compensation |
|
178,535 |
|
|
116,867 |
|
|||||
| Adjusted EBITDA | $ |
124,114 |
|
$ |
137,900 |
|
|||||
About HealthWarehouse.com
HealthWarehouse.com, Inc. (OTCQB:HEWA), a technology company with a focus on healthcare e-commerce, sells and delivers prescription medications to all 50 states as an Approved Digital Pharmacy through the National Association of Boards of Pharmacy (NABP). HealthWarehouse.com provides a platform focused on increasing access and reducing costs of healthcare products for consumers nationwide. Based in Florence, Kentucky, the Company operates America's Leading Online Pharmacy and a pioneer in affordable healthcare. As one of the first National Association of Boards of Pharmacy (“NABP”) Approved Digital Pharmacies, HealthWarehouse.com services the mission of providing affordable healthcare and incredible patient services to help Americans. Learn more at www.HealthWarehouse.com .
Forward-Looking Statements
This announcement and the information incorporated by reference herein contain “forward ¬looking statements” as defined in federal securities laws, including but not limited to Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which statements are based on our current expectations, estimates, forecasts and projections. Statements that are not historical facts, including statements about the beliefs, expectations and future plans and strategies of the Company, are forward-looking statements. Actual results may differ materially from those expressed in forward looking statements or in management's expectations. Important factors which could cause or contribute to actual results being materially and adversely different from those described or implied by forward looking statements include, among others, risks related to competition, management of growth, access to sufficient capital to fund our business and our growth, new products, services and technologies, potential fluctuations in operating results, international expansion, outcomes of legal proceedings and claims, fulfillment center optimization, seasonality, commercial agreements, acquisitions and strategic transactions, foreign exchange rates, system interruption, cyber-attacks, access to sufficient inventory, government regulation and taxation, payments, and fraud. More information about factors that potentially could affect HealthWarehouse.com's financial results is included in HealthWarehouse.com's audited Annual Reports and Quarterly Reports available at otcmarkets.com and prior filings with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005702/en/
FAQ
What were HealthWarehouse.com, Inc.'s net sales for Q1 2021?
What is the net loss for HealthWarehouse.com, Inc. in Q1 2021?
How did the Adjusted EBITDA of HealthWarehouse.com change in Q1 2021?
What was the percentage decrease in net sales for HealthWarehouse.com in Q1 2021?
What were the factors behind the decrease in HealthWarehouse.com’s prescription sales in Q1 2021?
